The Study
Abstract 3448: Discovery of HYP-2A,a 2nd- generation KRASG12C inhibitor exhibits potent in vivo efficacy in drug resistant tumor models
This study tested a new medicine in test tubes and mice, not people. It shows the medicine might stop cancer cells from growing in those settings, but that doesn't mean it will work in humans.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists made a new pill called HYP-2A that can kill cancer cells that no longer respond to two existing drugs, Sotorasib and Adagrasib.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 510 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — if this works in humans, it could help cancer patients whose tumors stopped responding to current treatments.
- 2HYP-2A shrank tumors by over 75% in mice at 10 mg/kg, while the old drugs barely worked even at 30 mg/kg.
- 3It killed cancer cells in a lab at doses as low as 1–99 nanomolar.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cancer Research
Year
2023
Authors
Shoujun Chen, X. Qiang, Haibo Wang, Yong Xiong, Ke Liu, D. Liao, N. Zhong, Mingdeng Liu, Xuemei Mu, Rudan Huang, Min Li, Dengwei Gui, Mei Huang, Yuting Chen, Yucheng Pan, Wen Yao, Y. Song, Zhongbo Wang, Wenbin Wang, Jun Liu, Xin Yu, Zhen Liang, Yike Yuan, Zhaoxi Ding
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.